CDNA Stock: Price, Earnings History and SEC Filings
CareDx, Inc. (CDNA) last traded at $87.41, up 22.22% on the latest session and up 34.5% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.52 against an analyst estimate of $0.07, a beat of 642.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CDNA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.52 | $0.07 | +642.86% |
| Jun 2026 | Jul 30, 2026 | $0.17 | $0.06 | +183.33% |
| Mar 2026 | Apr 28, 2026 | $0.05 | $-0.11 | +145.45% |
CDNA beat the analyst EPS estimate in 3 of its last 3 reported quarters. Source: Nasdaq.
How CDNA reacts to earnings
Across its last 8 earnings releases, CDNA moved 14.4% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | +22.22% |
| 2026-07-30 | After close | +14.72% |
| 2026-04-28 | After close | -5.07% |
| 2026-04-16 | Before open | +27.60% |
| 2026-02-24 | After close | -4.10% |
| 2026-01-12 | Before open | +20.08% |
| 2025-11-04 | After close | +13.84% |
| 2025-08-06 | After close | -7.86% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CDNA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $380M | -$21M | – | -5.6% | $-0.40 |
| 2024 | $334M | $53M | – | 15.7% | $0.93 |
| 2023 | $280M | -$190M | – | -67.9% | $-3.54 |
| 2022 | $322M | -$77M | – | -23.8% | $-1.44 |
| 2021 | $296M | -$31M | – | -10.3% | $-0.59 |
| 2020 | $192M | -$19M | – | -9.7% | $-0.40 |
| 2019 | $127M | -$22M | – | -17.3% | $-0.52 |
| 2018 | $77M | -$47M | -$6M | -61.1% | $-1.31 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CDNA
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jul 7, 2026Acquisition or disposal completed, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 15, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · Apr 28, 2026
- 8-K · Apr 28, 2026Material agreement, Results of operations, Regulation FD disclosure
- DEF 14A · Apr 27, 2026
- 8-K · Apr 16, 2026Material agreement, Results of operations, Regulation FD disclosure
Insider filing activity
CDNA insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CDNA news
- CareDx (CDNA) Stock Still Looks Reasonable Following Its Huge 3 Year RunOct 31, 2026 · finance.yahoo.com
- Why CareDx Stock Soared TodayOct 30, 2026 · fool.com
- CareDx (CDNA) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- What CareDx (CDNA) Said on Its Q3 Earnings CallOct 30, 2026 · marketbeat.com
- CareDx (CDNA) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- CareDx: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
- CareDx Announces Third Quarter 2026 Financial ResultsOct 29, 2026 · finance.yahoo.com
- CareDx (CDNA) After Kidney Week Data Is The Story Already Priced InOct 27, 2026 · finance.yahoo.com
About CareDx, Inc.
CareDx, Inc. (CDNA) is a US-listed public company on Nasdaq. The SEC classifies its business as Services-medical Laboratories. It is incorporated in DE. Its fiscal year ends in December.